Search
Close this search box.

PI – Sustainability Modeling

Support the advancement of innovation in methods and technologies into the Next Gen facility design to achieve carbon neutral bioprocessing.
Categories
Proteins/ Antibodies
Project status
96% Completed

Industry Need

Processes developers don’t know the sustainability impact of their decisions because modeling carbon footprint requires special expertise, significant effort, and there is no accepted standard method. 

Solution

Develop simple, easy-to-use approximate models suitable for use by process developers.

Outputs/Deliverables

  • LCA Modeling Tool (available now to NIIMBL members)
  • Biosolve Publication (In progress) 
  • LCA Publication (In progress)

Impacts

Sustainability of options for new processes and plants are known as design and development decisions are made, leading to more sustainable processes and plants

Additional Project Information (Members Only)

Login to the NIIMBL member portal to access more, including: 

  • Updates
  • Value Proposition
  • Related Publications
  • Deliverables

Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.

Project Lead

Genentech

Genentech

Participating Organizations

Amgen Inc.

Amgen Inc.

AstraZeneca

AstraZeneca

Bristol-Myers Squibb

Bristol-Myers Squibb

Cytiva

Cytiva

Eli Lilly and Company

Eli Lilly and Company

GlaxoSmithKline, LLC

GlaxoSmithKline, LLC

Merck Sharp & Dohme LLC

Merck Sharp & Dohme LLC

MilliporeSigma/EMD Serono

MilliporeSigma/EMD Serono

NIIMBL

NIIMBL

Pfizer, Inc.

Pfizer, Inc.

Sanofi

Sanofi

Sartorius Stedim

Sartorius Stedim

Takeda Pharmaceuticals

Takeda Pharmaceuticals

University of Delaware

University of Delaware